Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

imipenem-cilastatin-relebactam

A parenteral antibiotic preparation containing imipenem, cilastatin sodium and relebactam, with bactericidal activity. Imipenem, a broad spectrum beta-lactam carbapenem antibiotic, binds to and inactivates penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium, a renal dehydropeptidase inhibitor, reduces the breakdown of imipenem by renal dehydropeptidase. Relebactam, a beta-lactamase inhibitor, reduces the breakdown of imipenem by certain serine beta-lactamases among gram-negative bacteria. Imipenem is active against a wide range of gram-positive and gram-negative organisms, and the imipenem, cilastatin sodium and relebactam combination may be used to treat infections caused by resistant gram-negative bacteria.
Synonym:imipenem/cilastatin sodium/relebactam
US brand name:Recarbrio
Search NCI's Drug Dictionary